Flexion Therapeutics Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last twelve months. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics or view top-rated stocks.

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Flexion Therapeutics.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analyst estimates of $24.61 million.
View Flexion Therapeutics' earnings history.

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FLXN shares have decreased by 29.2% and is now trading at $8.72.
View which stocks have been most impacted by COVID-19.

Flexion Therapeutics updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $120 million-130 million, compared to the consensus revenue estimate of $133.77 million.

10 brokerages have issued twelve-month target prices for Flexion Therapeutics' shares. Their forecasts range from $14.00 to $35.00. On average, they expect Flexion Therapeutics' share price to reach $20.13 in the next twelve months. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for Flexion Therapeutics or view top-rated stocks among Wall Street analysts.

46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among Flexion Therapeutics' employees.

Some companies that are related to Flexion Therapeutics include Supernus Pharmaceuticals (SUPN), ADC Therapeutics (ADCT), Madrigal Pharmaceuticals (MDGL), Zymeworks (ZYME), Applied Molecular Transport (AMTI), Cerevel Therapeutics (CERE), Heron Therapeutics (HRTX), Constellation Pharmaceuticals (CNST), Arcus Biosciences (RCUS), Cytokinetics (CYTK), Amneal Pharmaceuticals (AMRX), NGM Biopharmaceuticals (NGM), Prelude Therapeutics (PRLD), Indivior (INVVY) and Y-mAbs Therapeutics (YMAB).
View all of FLXN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.04%), Wasatch Advisors Inc. (8.43%), Artisan Partners Limited Partnership (6.30%), Clearline Capital LP (2.81%), Versant Venture Management LLC (2.62%) and Goldman Sachs Group Inc. (2.04%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, David Arkowitz, Mark S Levine, Mark Stejbach, Melissa Layman, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Credit Suisse AG, Versant Venture Management LLC, Russell Investments Group Ltd., American Financial Group Inc., Royce & Associates LP, Northern Trust Corp, and Nuveen Asset Management LLC. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, David Arkowitz, Mark S Levine, and Melissa Layman.
View insider buying and selling activity for Flexion Therapeutics or view top insider-selling stocks.

FLXN stock was bought by a variety of institutional investors in the last quarter, including Clearline Capital LP, Goldman Sachs Group Inc., JPMorgan Chase & Co., BlackRock Inc., Millennium Management LLC, Citigroup Inc., GAM Holding AG, and Jane Street Group LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include Mark Stejbach, Michael D Clayman, and Samuel D Colella.
View insider buying and selling activity for Flexion Therapeutics or or view top insider-buying stocks.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLXN stock can currently be purchased for approximately $8.72.

Flexion Therapeutics has a market capitalization of $435.49 million and generates $85.55 million in revenue each year. The specialty pharmaceutical company earns $-113,710,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

Flexion Therapeutics employs 257 workers across the globe.

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

Flexion Therapeutics is headquartered at 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]